Astrazeneca Could Buy Bristol Stake In Diabetes Jv: Analyst

Bristol said on Thursday it would no longer conduct research to discover new drugs for diabetes, hepatitis C and neuroscience, but will increase spending on medicines that harness the immune system to fight cancer. That refocusing suggests Bristol could seek to sell its share in the non-U.S. part of the diabetes joint venture to its partner AstraZeneca, Citi analyst Andrew Baum said in a note on Friday. Citi estimated Bristol’s stake in the business outside the United States could be worth $4 billion to $6 billion and the acquisition would boost AstraZeneca’s earnings per share by between 1 percent and 5 percent over the medium term.
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/11/08/us-bristolmeyers-astrazeneca-idUSBRE9A70F020131108

Diabetes increased CAD risk in young, middle-aged women

men with diabetes: GeneSTAR (17.65 vs. 12.86 per 1,000 person-years); MESA (7.34 vs. 9.71 per 1,000 person-years); and NHANES (2.37 vs. 1.83 per 1,000 person-years).
For the original version including any supplementary images or video, visit http://www.healio.com/endocrinology/cardiometabolic-disorders/news/online/{4e1757cb-a088-48de-ae81-2d6c9641f765}/diabetes-increased-cad-risk-in-young-middle-aged-women

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s